Early halted trial explores new way to treat rare childhood hormone disorder
NCT ID NCT02574910
Summary
This early-stage study tested whether adding a medication called abiraterone acetate to standard treatment could help young children with a rare inherited hormone disorder (congenital adrenal hyperplasia) safely reduce their daily steroid dose. The goal was to find the lowest effective dose that could control hormone levels, potentially helping children avoid side effects from high steroid use. The study was terminated early after enrolling only four participants, so no clear conclusions could be drawn.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Los Angeles
Los Angeles, California, 90027, United States
-
Children's Medical Center
Dallas, Texas, 75235, United States
-
National Institutes of Health
Bethesda, Maryland, 20892-1932, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.